1- 289-270-4933
North Macedonian medical cannabis disruptor with EU-GMP compliant facility and proprietary digital platform/IPs
A UK-based ownership group, with North Macedonia's EU-GMP compliant manufacturing facility, boasts exclusive manufacturing capability, a proprietary digital platform, and an industry-leading low-cost structure
Listing ID:
18598094464
Licence(s) Held:
Regulatory license held for the manufacturing, R&D, processing, packaging and import/ export of medicinal cannabis globally includes flower, extracts and final product
Seeking strategic investment of €2.5 million
Listing Details:
Headquarted in London, UK, this medical cannabis company strategically leverages a low-cost manufacturing facility in North Macedonia to access the supply chain, while maintaining its focus on higher-value activities further along the chain
Construction completed on a ~2,500 m² EU GMP designed manufacturing, R&D, processing and packaging facility
Facility is capable of tolling 1000 KG’s of dried flower per month (i.e. GACP to GMP conversion), extraction capacity of 130 lts per month (EU-GMP) and further capabilities for packaging, white labeling, finished product, and stability chambers
25 acres of commercial land owned and 5 acres are licensed for production and outdoor cultivation
Company has developed proprietary platforms for wholesale (i.e. suppliers, distributors), end patient (i.e. patients and prescribers) clinician evidence, and data/ IA platforms.
World-class team with domain and industry leadership spanning medical, pharmaceuticals, technology and cannabinoids
Have established a number of key relationships with clinics, distributors, university partners and other commercial partners
Diversified supply agreements are in place and multiple LOIs/contracts are underway
Exclusive partnership for core set of stable genetics
With a portfolio comprising 12 vaporized formulations, the company is poised to lead the medical cannabis vaporizer market through exclusive partnership with leading UK Clinic & German distributor; targeting launches in the UK, German, and Australian markets
Anticipating ~€4 million in annual revenue in 2024
Exclusive contract for the cultivation and supply to a UK cannabinoid FDA Botanical Pathway Drug Development company
Strategically positioned as a key gateway for importing and exporting cannabis and cannabis products to and from North Macedonia, poised to emerge as a prominent force in pioneering cannabinoid-based medication and technology within Europe
The company seeks €2.5 million investment to achieve EU-GMP certification and introduce its unique products into the European and global markets
18598094464